Evidence map›Paper›PMID 30503263›Full record

ArticleStem cell reports2018

Increased Calcium Influx through L-type Calcium Channels in Human and Mouse Neural Progenitors Lacking Fragile X Mental Retardation Protein.

Claudia Danesi, Venkat Swaroop Achuta, Padraic Corcoran, Ulla-Kaisa Peteri, Giorgio Turconi, Nobuaki Matsui, Ilyas Albayrak, Veronika Rezov, Anders Isaksson, Maija L Castrén

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06480968 phase1completednot on this mapstarted 2023, after this paper: background citation

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2023 to 2024Enrolled76ConditionsFragile X SyndromeArmsCTH120, Placebo
NCT06957054 completednot on this mapstarted 2024, after this paper: background citation

Assessment of Neural Biomarkers in Adult Subjects With Fragile X Syndrome and Typically Developing Subjects

TypeobservationalSponsorConnecta Therapeutics, S.L.Ran2024 to 2025Enrolled20ConditionsFragile X Syndrome (FXS), Neurotypical AdultsArmsAny
NCT07654114 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2026 to 2027Enrolled30ConditionsFragile X Syndrome (FXS), Fragile X SyndromeArmsCTH120, CTH120 placebo hard capsules
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. ReducedFrontiers in cell and developmental biology · 2022
    Article
  5. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing CaThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  6. Review
  7. Hyperexcitability and Homeostasis in Fragile X Syndrome.Frontiers in molecular neuroscience · 2021
    Article
  8. Article
  9. Review
  10. Review
  11. Dysregulated CaFrontiers in synaptic neuroscience · 2019
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Claudia DanesiFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Venkat Swaroop AchutaFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Padraic CorcoranArray and Analysis Facility, Department of Medical Sciences, Uppsala University, PO Box 3056, 75003 Uppsala, Sweden.
Ulla-Kaisa PeteriFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Giorgio TurconiFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Nobuaki MatsuiDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, 770-8514, Japan.
Ilyas AlbayrakFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Veronika RezovFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland.
Anders IsakssonArray and Analysis Facility, Department of Medical Sciences, Uppsala University, PO Box 3056, 75003 Uppsala, Sweden.
Maija L CastrénFaculty of Medicine, Physiology, University of Helsinki, PO Box 63, FIN-00014 University of Helsinki, Helsinki, Finland. Electronic address: maija.castren@helsinki.fi.
University of Helsinki · FIUppsala University · SETokushima Bunri University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The absence of FMR1 protein (FMRP) causes fragile X syndrome (FXS) and disturbed FMRP function is implicated in several forms of human psychopathology. We show that intracellular calcium responses to depolarization are augmented in neural progenitors derived from human induced pluripotent stem cells and mouse brain with FXS. Increased calcium influx via nifedipine-sensitive voltage-gated calcium (Ca

Indexed as

AnimalsBrain-Derived Neurotrophic FactorCalciumCalcium Channels, L-TypeCell DifferentiationCell MovementFragile X Messenger Ribonucleoprotein 1Gene DeletionHumansInduced Pluripotent Stem CellsMembrane PotentialsMice, Inbred C57BLMice, KnockoutNeural Stem CellsPhosphorylationProtein SubunitsBrain-Derived Neurotrophic FactorCalciumCalcium Channels, L-TypeFragile X Messenger Ribonucleoprotein 1metabotropic glutamate receptor type 1Protein SubunitsReceptors, Metabotropic GlutamateReceptor, trkBBDNFfragile X syndromeglutamate receptorsintracellular calciumneural progenitorsvoltage-gated calcium channels

Identifiers

PMID30503263
PMCPMC6294261
OpenAlexW2902836816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.